Replies to post #133227 on Biotech Values

[mcbio]

I'm not sure how much can be garnered from this, especially since it is a comparison between a phase III trial with an n of 337 is being compared with a phase I trial with an n of 9.

Absolutely. Very fair caveat.

That's what I heard too, and if that's true it does seem quite promising. I'm just surprised he is talking about it before it's been presented at a scientific meeting.

Yeah, I went back and listened several times after I posted and it's pretty clear what the speaker said. The only question could be if he somehow misspoke. Also, I will keep my expectations tempered until after the presentation because I did scroll through to the 2012 milestones and for whatever reason ARRY doesn't list the presentation of the MEK162 Phase 1b biliary tract cancer data as a 2012 milestone. One would think this would be listed as a clear milestone if what the speaker said is indeed true. Perhaps it was an oversight. Perhaps not. It will be interesting to see the data.